research use only

CC-90001 JNK inhibitor

Name: CC-90001
Brand: Selleck Chemicals
SKU: S9614
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S9614

CC-90001 is an orally administered inhibitor of c-Jun N-terminal kinase (JNK) with bias for JNK1 over JNK2. It exhibits antifibrotic efficacy and can be used for the research of idiopathic pulmonary fibrosis.

Chemical Structure

Molecular Weight: 321.42

Jump to

Quality Control

Batch: S961401 DMSO]32 mg/mL]false]Ethanol]32 mg/mL]false]Water]Insoluble]false Purity: 99.28%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS/MSDS
Datasheet

99.28

Related Targets	ERK p38 MAPK Raf MEK Ras KRas S6 Kinase MAP4K TAK1 Mixed Lineage Kinase
Other JNK Inhibitors	SP600125 JNK-IN-8 Anisomycin (Flagecidin) JNK Inhibitor IX Tanzisertib Hydrochloride (CC-930) JNK Inhibitor VIII Bentamapimod (AS602801) Polyphyllin I BI-78D3 DTP3

Solubility

In vitro
Batch:

DMSO : 32 mg/mL (99.55 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 32 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.600mg/ml (4.98mM)	Taking the 1 mL working solution as an example, add 50 μL of 32 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.600mg/ml (4.98mM)	Taking the 1 mL working solution as an example, add 50 μL of 32 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	321.42	Formula	C₁₆H₂₇N₅O₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1403859-14-2	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	JNK JNK1 JNK2
References	[1] https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A5409 [2] https://pubmed.ncbi.nlm.nih.gov/35058236/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-06-13)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05625412	COMPLETED	Advanced Solid Tumors	Bristol-Myers Squibb	2022-12-09	PHASE1
NCT03142191	TERMINATED	Idiopathic Pulmonary Fibrosis; Fibrosis; Idiopathic Interstitial Pneumonias; Pathologic Processes; Lung Diseases, Interstitial; Lung Diseases; Respiratory Tract Diseases	Celgene	2017-07-26	PHASE2
NCT04048876	TERMINATED	Non-alcoholic Fatty Liver Disease; Liver Cirrhosis	Celgene	2019-08-14	PHASE2
NCT04655898	COMPLETED	Healthy Volunteer	Celgene	2020-12-16	PHASE1
NCT03958864	COMPLETED	Healthy Volunteer	Celgene	2019-04-04	PHASE1
NCT03742882	COMPLETED	Hepatic Impairment	Celgene	2018-12-06	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):